A hybrid phase I‐II/III clinical trial design allowing dose re‐optimization in phase III (Q5214489)

From MaRDI portal
Revision as of 21:53, 19 March 2024 by Openalex240319060354 (talk | contribs) (Set OpenAlex properties.)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
scientific article; zbMATH DE number 7165177
Language Label Description Also known as
English
A hybrid phase I‐II/III clinical trial design allowing dose re‐optimization in phase III
scientific article; zbMATH DE number 7165177

    Statements

    A hybrid phase I‐II/III clinical trial design allowing dose re‐optimization in phase III (English)
    0 references
    0 references
    0 references
    0 references
    7 February 2020
    0 references
    Bayesian design
    0 references
    clinical trial
    0 references
    dose finding
    0 references
    phase I-II clinical trial
    0 references
    phase III clinical trial
    0 references

    Identifiers